References
- American Academy of Pediatrics Committee on Infectious Diseases. Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics. 2005;116(2):496–505
- Centers for Disease Control and Prevention. Summary of notifiable diseases—United States, 2007. Published July 9, 2009 for MMWR. 2007;56(No. 53):1–100
- Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 11th ed. Washington, DC: Public Health Foundation; 2009
- . Centers for Disease Control and Prevention. Prevention and Control of Meningococcal Disease Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2005;54(No. RR-7):1–21
- Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 1997-2008. http://www.cdc.gov/abcs/reports-findings/surv-reports.html. Accessed February 24, 2010
- Centers for Disease Control and Prevention. Meeting of The Advisory Committee on Immunization Practices (ACIP). Epidemiology of Meningococcal Disease in Infants and Young Children; October 21–22, 2009; Atlanta, GA
- National Foundation for Infectious Diseases. The changing epidemiology of meningococcal disease among US children, adolescents and young adults. 1–15. http://www.nfid.org/pdf/meningitis/FINALChanging_Epidemiology_of_Meningococcal_Disease.pdf. Accessed February 1, 2010
- Greenfield S, Sheehe PR, Feldman HA. Meningococcal carriage in a population of “normal” families. J Infect Dis. 1971;123(1):67–73
- Caugant DA, Høiby EA, Magnus P, . Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol. 1994;32(2):323–330
- Cartwright KA, Stuart JM, Jones DM, Noah ND. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect. 1987;99(3):591–601
- Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969;129(6):1327–1348
- Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307–1326
- Pollard AJ, Frasch C. Development of natural immunity to Neisseria meningitidis. Vaccine. 2001;19(11–12):1327–1346
- Kirsch EA, Barton RP, Kitchen L, Giroir BP. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J. 1996;15(11):967–978
- Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr. 1981;99(4):540–545
- Centers for Disease Control and Prevention. Manual for the Surveillance of Vaccine-Preventable Diseases. 4th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2008
- Sáez-Llorens X, McCracken GH. Acute bacterial meningitis beyond the neonatal period. In: Long SS, Pickering LK, Prober CG, eds. Principles and Practice of Pediatric Infectious Disease. 3rd ed. Philadelphia, PA: Churchill Livingston/Elsevier; 2008
- Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices. Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate All Persons Aged 11–18 years with Meningococcal Conjugate Vaccine. MMWR Morb Mortal Wkly Rep. 2007;56(31):794–795
- Centers for Disease Control and Prevention. Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in Children Aged 2–10 years at Increased Risk for Invasive Meningococcal Disease. MMWR Morb Mortal Wkly Rep. 2007; 56(48):1265–1266
- Centers for Disease Control and Prevention. Recommended Immunization Schedule for Persons aged 0–6 years—United States 2009. http://www.cdc.gov/vaccines/recs/schedules/child-schedule.htm. Accessed February 14, 2009
- Centers for Disease Control and Prevention. Recommended adult immunization schedule—United States, 2009. MMWR. 2009;57(53):Q1–Q4